Entheon Biomedical Corp
Entheon Biomedical Corp. operates as a biotechnology research and development company. The company develops products for treating addiction and substance use disorders. Entheon Biomedical Corp. is headquartered in Vancouver, Canada.
Entheon Biomedical Corp (ENTBF) - Total Assets
Latest total assets as of March 2025: $452.26K USD
Based on the latest financial reports, Entheon Biomedical Corp (ENTBF) holds total assets worth $452.26K USD as of March 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Entheon Biomedical Corp - Total Assets Trend (2018–2025)
This chart illustrates how Entheon Biomedical Corp’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Entheon Biomedical Corp - Asset Composition Analysis
Current Asset Composition (March 2025)
Entheon Biomedical Corp's total assets of $452.26K consist of 97.3% current assets and 2.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 73.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Entheon Biomedical Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Entheon Biomedical Corp's current assets represent 97.3% of total assets in 2025, an increase from 70.9% in 2018.
- Cash Position: Cash and equivalents constituted 73.7% of total assets in 2025, up from 61.5% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Entheon Biomedical Corp Competitors by Total Assets
Key competitors of Entheon Biomedical Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Entheon Biomedical Corp - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Entheon Biomedical Corp generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Entheon Biomedical Corp is currently not profitable relative to its asset base.
Entheon Biomedical Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 27.75 | 7.95 | 41.28 |
| Quick Ratio | 27.75 | 7.95 | 41.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $431.14K | $ 288.83K | $ 1.13 Million |
Entheon Biomedical Corp - Advanced Valuation Insights
This section examines the relationship between Entheon Biomedical Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.84 |
| Latest Market Cap to Assets Ratio | 5.39 |
| Asset Growth Rate (YoY) | -53.8% |
| Total Assets | $185.14K |
| Market Capitalization | $997.84K USD |
Valuation Analysis
Premium Asset Valuation: The market values Entheon Biomedical Corp's assets at a significant premium ( 5.39x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Entheon Biomedical Corp's assets decreased by 53.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Entheon Biomedical Corp (2018–2025)
The table below shows the annual total assets of Entheon Biomedical Corp from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $185.14K | -53.84% |
| 2024-03-31 | $401.08K | -47.86% |
| 2023-03-31 | $769.22K | -92.29% |
| 2022-03-31 | $9.98 Million | +123.06% |
| 2021-03-31 | $4.47 Million | +159.82% |
| 2020-03-31 | $1.72 Million | -6.58% |
| 2019-03-31 | $1.84 Million | +229.64% |
| 2018-03-31 | $559.05K | -- |